Core Insights - Shanghai Yizhong (688091) reported a significant increase in revenue and profit for 2025, with total revenue reaching 317 million yuan, representing a year-on-year growth of 82.72% [1] - The net profit attributable to shareholders was 64.132 million yuan, showing an impressive year-on-year increase of 819.42% [1] - The company's core product, injectable paclitaxel polymer micelles, was officially included in the national medical insurance directory in 2025, which greatly enhanced market access and the number of patients using the product, driving revenue and profit growth for the year [1]

Core Viewpoint - Shanghai Yizhong (688091.SH) reported significant growth in its 2025 financial performance, driven by the inclusion of its core product, paclitaxel polymer micelles, in the national medical insurance catalog [1] Financial Performance - The company achieved an operating revenue of 317 million yuan in 2025, representing a year-on-year increase of 82.72% [1] - The net profit attributable to the parent company was 64.132 million yuan, showing a remarkable year-on-year growth of 819.42% [1] Product Impact - The inclusion of paclitaxel polymer micelles in the national medical insurance catalog significantly boosted market access and the number of patients using the product, contributing to the overall revenue and profit growth for the year [1]

Core Viewpoint - Shanghai Yizhong (688091.SH) forecasts a net profit attributable to shareholders of the parent company for 2025 to be between 60 million and 70 million yuan, representing a growth of 760.18% to 903.54% compared to the same period last year [1] Group 1: Financial Performance - The expected net profit for 2025 is projected to be between 60 million and 70 million yuan [1] - This represents a significant increase of 760.18% to 903.54% compared to the previous year [1] Group 2: Key Drivers of Performance - The primary reason for the performance change is the inclusion of the company's core product, paclitaxel polymer micelles, in the national medical insurance catalog in 2025 [1] - This inclusion is expected to significantly enhance market access and the number of patients using the product, leading to substantial growth in revenue and profit compared to 2024 [1]